Clinical trials: Regression
HIV Infections
Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women
The primary objective of the study was to evaluate the efficacy of nevirapine versus ZDV+3TC (Zidovudine + Lamivudine), when administered in labor and again at postdelivery, in reducing peripartum mother to child transmission of…
- Trial name
- NCT02181933
- Testing
- Nevirapine, Zidovudine (ZDV), Lamivudine (3TC)
- Volunteers
- 2,648 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure
The study is to evaluate the safe admission avoidance and the overall economic impact associated with management of worsening HF using the drug-device combination product, the Furoscix Infusor, outside the hospital setting in…
- Trial name
- FREEDOM-HF (NCT03458325)
- Testing
- Furoscix Infusor
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- scPharmaceuticals, Inc.
Acute Coronary Syndrome
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Cardiovascular disease remains the most pressing healthcare issue for developed countries and is becoming so for developing countries. There are a number of chronic therapies available for long-term management of risk.
- Trial name
- CHI SQUARE (NCT01201837)
- Testing
- CER-001
- Where
- 47 sites in United States, Canada and 2 more
- Volunteers
- 507 people
- Sponsor
- Cerenis Therapeutics, SA
Down Syndrome
A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.
The purpose of this double-blind, placebo-controlled, comparative study and open-label extension study is to confirm the efficacy and safety of E2020 in subjects with Down syndrome having regression symptoms and disabled…
- Trial name
- NCT02094053
- Testing
- E2020-Donepezil hydrochloride
- Where
- 10 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Eisai Co., Ltd.
Polypoidal Choroidal Vasculopathy
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with…
- Trial name
- PCV (NCT00674323)
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 5 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 61 people
- Sponsor
- Novartis
Opioid Misuse
Decreasing Opioid Misuse and Habit-forming Behaviors Following Prescription in Patients Undergoing Cesarean Section
Background: Cesarean delivery is one of the most common obstetric procedures experienced among women who are pregnant.1 Women with Cesarean deliveries have a higher rate of peripartum opioid prescriptions and persistent opioid…
- Trial name
- NCT05461196
- Testing
- CPMRx
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Jessica Morgan
Amputation, Amputation; Traumatic, Hand
EMG-Based Hand-Wrist Control: Study B Mirrored
Study assessing four-channel prosthesis controller, that compares contralateral (mirrored) EMG-force training to ipsilateral EMG-target training with both limb-absent and able-bodied subjects
- Conditions
- Amputation, Amputation; Traumatic, Hand, Amputation, Congenital, Prosthesis User
- Trial name
- PSICON-B (NCT04692571)
- Testing
- PSICON Measurement Apparatus
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Liberating Technologies, Inc.
Schizophrenia, Schizoaffective Disorder
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00139919
- Testing
- Bifeprunox
- Where
- United States
- Sponsor
- Solvay Pharmaceuticals
Allergic Rhinitis
Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing Symptoms of Allergic Rhinitis
A nasal spray based on Advanced Water S-100 ionized water would clean the nasal cavities, reduce the viscosity of mucus and facilitate its elimination and decongestion of the nose and the prevention of the bridging of the…
- Trial name
- SPRA (NCT05443945)
- Testing
- Nasal Spray
- Where
- 11 sites in France
- Volunteers
- 95 people
- Sponsor
- P & B Group
Musculoskeletal Pain, Fear of Falling
Free From Pain Exercise Programme Study
To determine the effectiveness of the "Free from Pain" exercise and information programme. The complete programme provides exercises and information for people over the age of 60 to reduce early osteoarthritic and generalised…
- Trial name
- NCT05091671
- Testing
- Free From Pain Exercise Programme Variation 1, Free From Pain Exercise Programme Variation 2
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Talita Cumi Ltd.
Photoaging
Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers
Ultraviolet light A (UVA) causes oxidization of guanine to mutagenic 8-Oxoguanine (8-OxoG) and the most frequent and best characterized mutation in mitochondrial DNA (mtDNA), a deletion of 4,977 base pairs, called the "common…
- Trial name
- CNXR-001D (NCT05279495)
- Testing
- In a double-blinded fashion, 250 mg CANNAXR cream, Topical VEHICLE cream
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MINO Labs, LLC
SARS-CoV-2 Infection
Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing SARS-Cov-2 Viral Load.
A nasal spray based on Advanced Water S-100 ionized water would clean the nasal cavity, reduce the viscosity of the mucus and facilitate its elimination and the decongestion of the nose and the prevention of the seizure of the…
- Trial name
- NCT05290987
- Testing
- nasal spray
- Where
- France
- Volunteers
- 13 people
- Sponsor
- P & B Group
Rett Syndrome
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
The primary objectives of this study are to evaluate the safety of a single intrathecal (IT) dose of TSHA-102 in females with typical Rett syndrome, to select the TSHA-102 dose with the best benefit/risk profile based on the…
- Trial name
- NCT05606614
- Testing
- TSHA-102
- Where
- 9 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Taysha Gene Therapies, Inc.
Breast Cancer
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
The aim of this study is to assess the safety and efficacy of neoadjuvant hormone therapy with letrozole in postmenopausal women with estrogen- and/or progesterone-receptor positive primary breast cancer on tumour regression to…
- Trial name
- NCT00330317
- Testing
- letrozole
- Where
- 20 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Lung Transplant
Decreasing Edema With a Novel OCS Solution Trial
This is a prospective, multicenter randomized trial of lung transplant recipients transplanted with either a DBD or DCD donor lungs.
- Trial name
- DENOVO (NCT07340710)
- Testing
- OCS Lung System, Static Cold Storage
- Volunteers
- 450 people
- Sponsor
- TransMedics
Obesity, Microalbuminuria
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
Primary objective: To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.
- Conditions
- Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia
- Trial name
- RIALTO (NCT00458081)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Sanofi
Human Papilloma Virus
Efficacy of Intravaginal Carboxymethyl-β-glucan and Polycarbophil on Low-grade Cervical Lesions (GLUCANCIN)
A therapeutic strategy to neutralize the evasion mechanisms of HPV. Among these treatments are beta-glucans, polysaccharides of beta-D-glucose that, can influence the clearance of HPV.
- Trial name
- GLUCANCIN (NCT04771546)
- Testing
- Colpofix
- Where
- 5 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Uriach Consumer Healthcare
Atherosclerosis, Coronary Artery Disease
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors…
- Trial name
- PURIFY-TIMI 81 (NCT07521007)
- Where
- 56 sites in United States, Australia and 2 more
- Volunteers
- 456 people
- Sponsor
- Beijing Inno Medicine Co., Ltd.
Rett Syndrome
Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.
- Trial name
- ASPIRE (NCT07480564)
- Testing
- TSHA-102
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Taysha Gene Therapies, Inc.
Coronary Artery Disease, Coronary Atherosclerotic Disease
YN001-004 in Patients With Coronary Atherosclerosis in Australia
This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia.
- Trial name
- NCT06700720
- Testing
- Dose 1 YN001, Dose 2 YN001, Evolocumab
- Where
- 6 sites in Australia
- Volunteers
- 3 people
- Sponsor
- Beijing Inno Medicine Co., Ltd.